Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Obinutuzumab Injection

In combination with chemotherapy, it is used for the treatment of patients with stage II with bulky, stage III or stage IV follicular lymphoma who have just been treated. Patients who achieve at least partial remission can then receive maintenance therapy with Otuzumab. [1] As the world’s first glycosylated humanized anti-CD20 monoclonal antibody, Otuzumab’s innovative structure and mechanism can enhance the killing of tumor cells to improve the progression-free survival rate of patients. This product is used in combination with chemotherapy for adult patients with stage II with bulky, stage III or stage IV follicular lymphoma who have just been treated. Patients who achieve at least partial remission can then receive maintenance therapy with Otuzumab. [1]
Standard dose
The recommended dose of Otuzumab is 1000 mg intravenously, as shown in Table 2.
For patients with treatment-naïve follicular lymphoma, obinutuzumab should be given in combination with chemotherapy as follows:
● 6 cycles of 28 days each, given in combination with bendamustine 1, or
● 6 cycles of 21 days each, given in combination with CHOP, followed by 2 additional cycles of obinutuzumab monotherapy, or
● 8 cycles of 21 days each, given in combination with CVP.
Patients who achieve a complete or partial response after an initial 6 or 8 cycles of obinutuzumab plus chemotherapy should continue to receive maintenance monotherapy with obinutuzumab (1000 mg) every 2 months until disease progression or up to 2 years.
Maintenance monotherapy should be initiated approximately 2 months after the last dose of obinutuzumab during the induction phase. [3]
Hepatic impairment: The safety and efficacy of obinutuzumab in patients with hepatic impairment have not been established. Renal Impairment In patients with mild or moderate renal impairment (CrCl 30-89 mL/min), no dose adjustment is required. The safety and efficacy of oletuzumab have not been studied in patients with CrCl < 30 mL/min (see Patients with Impaired Renal Function and Pharmacokinetics for Pharmacokinetics in Specific Populations).
Elderly: No dose adjustment is recommended in patients aged ≥ 65 years (see Geriatric Use). Children The safety and efficacy of oletuzumab have not been established in patients younger than 18 years. [3]

Share: